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Synaptic adhesion molecules, including presynaptic neurexins (NRXNs) and post-synaptic leucine-
rich repeat transmembrane (LRRTM) proteins are important for development and maintenance of 
brain neuronal networks. NRXNs are probably the best characterized synaptic adhesion molecules, 
and one of the major presynaptic organizer proteins. The LRRTMs were found as ligands for 
NRXNs. Many of the synaptic adhesion proteins have be n linked to neurological cognitive 
disorders, such as schizophrenia and autism spectrum disorders, making them targets of interest 
for both biological studies, and towards drug development. Therefore, we decided to develop a 
screening method to target the adhesion proteins, here the LRRTM-NRXN interaction, to find 
small molecule probes for further studies in cellular settings. To our knowledge, no potent small 
molecule compounds against the neuronal synaptic adhesion proteins are available. We utilized 
the AlphaScreen technology, and developed an assay targeting the NRXN-LRRTM2 interaction. 
We carried out screening of 2000 compounds and identified hits with moderate IC50-values. We 
also established an orthogonal in-cell western blotassay to validate hits. This paves way for 
future development of specific high affinity compounds by further high throughput screening of 
larger compound libraries using the methods established here. The method could also be applied 









The synaptic adhesion molecules such as presynaptic neurexins (NRXNs) and post-synaptic leucine-
rich repeat (LRR) proteins including the LRR transmembrane (LRRTM) family of proteins are 
important for the development and maintenance of brain and formation of neuronal networks. 
Synapses are the major contact and information relay points between the individual neurons that 
constitute the neuronal network of the brain [1, 2]. NRXNs are probably the best characterized 
synaptic adhesion molecules [3, 4, 5, 6]  and one of the major presynaptic organizer proteins [7].  
 
Mammals have three NRXN genes (NRXN1-3), and each NRX  gene produces two isoforms, 
NRXNα and NRXNβ. In addition, NRXNs can produce potentially thousands of different splice 
variants [6]. The NRXNαs have five canonical splice sites, SS1-SS5, of which SS4 and SS5 are 
also present in the NRXNβ genes [3]. The NRXN interactions are largely Ca2+ dependent [3]. 
They have several post-synaptic ligands such as neuroligins [8], LRRTMs[4], neuroxophilin, 
dystroglycan [9], cerebellin [10] and calsyntenins [11]. The NRXNs and LRRTM interaction 
requires the splice form lacking the SS4 splice sitequence [12]. NRXNs family proteins are 
found in both excitatory and inhibitory synapses. The extracellular part of NRXNs constitutes of 
LNS (laminin, NRXN and sex-hormone-binding protein) and EGF domains. NRXNα has 6 LNS 
domains (L1-6), arranged in three modules with EGF domains (E1-3) between two LNS domains 
(Fig. 1A). NRXNβ contains only one LNS-domain, identical to the NRXN-α LNS6, after which 
there is a highly glycosylated linker region and a tr nsmembrane (TM) domain and an 
intracellular tail with a PDZ binding motif, that interacts with the presynaptic organizing 
machinery [3]. Structures of both partial NRXNα ectodomain and various NRXNβ constructs 
alone and in complex with neuroligin ligands have been resolved by X-ray crystallography [13, 
14, 15, 16] .  
 
The LRRTM family of proteins that include four members are found in the excitatory 
glutamatergic synapses of the brain and were found originally as ligands of NRXNs [17, 18, 19]. 
LRRTMs all share the same domain organization with N-terminal extracellular domain with ten 
repeat LRR domain followed by a linker region and TM domain, and intracellular tail with a PDZ 
binding motif (Fig. 1A) anchoring the LRRTMs to post-synaptic density organizing proteins and 
the glutamate receptors. We have earlier solved the s ructure of engineered thermostabilized 
LRRTM2 extracellular domain [20] and recently the LRRTM2-NRXNβ1 complex crystal 
structure was solved [21], revealing the interaction interface, located surprisingly in the helical C-
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terminal capping region of the LRR domain on LRRTM2 (Fig. 1B). Further, in particular 
LRRTM4, but probably also other LRRTMs, have also been found to be ligands for heparan 
sulphate proteoglycans [18, 22]. It has been suggested that NRXNs are post-translationally 
decorated with heparan sulphate in the membrane proximal region of the extracellular domain and 
this might increase the affinity towards LRRTMs [23]. Other ligands are currently not known for 
LRRTMs, and thus their ligand repertoire is not as wide as for NRXNs. 
 
Many of the synaptic adhesion proteins have been genetically linked to neuronal disorders, in 
particular, cognitive disorders such as schizophrenia, autism spectrum disorders and bipolar 
disorder [24, 25], which make them targets of interest for biological, therapeutic and disease 
mechanism studies in model organisms or in cell culture. For the functional studies of synaptic 
adhesion proteins, both gain-of-function and loss-of-function studies have been important.  
However, overall loss-of-function studies would benefit from specific compounds that target a 
particular interaction, e.g. studies with knock-out animals or neuronal cultures would be potential 
applications for such effector molecules. Loss-of-function studies have involved generation of 
knock-down and knock-out mice for various adhesion proteins. For NRXNs, neuroligins and 
LRRTMs it has been shown that single knock-downs are not necessarily lethal and probably single 
knock-downs can be compensated functionally by the o r homologs or ligands to some extent [17], 
while triple NRXNα knock-outs are lethal [26, 27]. Currently, no inhibitor compounds for these 
synaptic adhesion proteins are available to our knowledge. Therefore, we have taken up the task 
to develop a screening method to target adhesion prtein interactions, here, the LRRTM-NRXN 
interaction. We utilized the AlphaScreen technology[28] (Fig. 1B) and developed an assay for 
screening compounds targeting the LRRTM-NRXN interaction. We carried out validatory 
screening and identified several hits with moderate IC50-values in the range of tens of 
micromolar. We also established and used an orthogonal assay to validate the potency of the hits 
in a cell-based assay. This setup paves way for the future development of specific high-affinity 
compounds either through optimization of the obtained hit compounds or by further high 
throughput screening of larger compound libraries using the methods established here.   
 
2. Materials and methods 
 
2.1 Cloning, protein expression and purification  
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Extracellular regions of the mouse LRRTM2 (LRRTM230-421) and NRXNα1 (NRXNα131-1286, 
lacking the SS4 splice site) were cloned into Drosophila pRMHA3 expression vector [29]. The 
expression constructs included a CD33 signal sequence at the N-terminus of the insert and a C-
terminal Fc-tag. LRRTM2-Fc was expressed from stably transfected Drosophila S2 cells, and 
expressed and purified as described previously [20].  
 
NRXNα1-Fc protein construct was expressed from stably transfected Drosophila S2 
cells.  Expression was verified by transient transfection using western blot method with goat 
polyclonal horse radish peroxidase (HRP) conjugated ntibody (Abcam, ab98567) against human 
IgG-Fc. For expression from stable cell line of S2 cells, 1.25 ×106 cells per well were plated on a six-
well plate at room temperature. After 24 hours, thecells were transfected with 4 µg of DNA 
containing 1:20 part of selection plasmid pCoHygro. The DNA was diluted into 400 µL of the 
medium; 8 µL of TransIT insect reagent (Mirus Bio LLC) was mixed with the DNA, and the mixture 
was incubated for 20 min and added to the cells. After 3 days, the selection was started; the cells and 
medium were centrifuged and the cells were resuspended into medium with 0.3 mg/mL hygromycin 
and re-plated into the same wells. After 3 weeks, the cells were grown in T75 flask (ThermoFischer). 
The cells were passaged every 6 days in T75 flask until the cell viability was above 95%. For large 
scale purification from the generated stable cell line, the S2 cells were diluted 1:10 into HyQ-SFX 
(ThermoFischer) medium supplemented with 0.15 mg/mL hygromycin, grown in shaker at 25°C for 
1 day, and induced with 0.7 mM CuSO4, and expression was conducted for further 6 days, after 
which the medium was harvested and cells were pelleted by centrifugation at 7000 rpm for 20 min at 
4°C. The protein was purified using the C-terminal Fc-fusion tag with protein-A sepharose 
(Invitrogen). Samples were eluted with 0.1 M glycine (pH 3.0) directly to neutralizing buffer, 60 mM 
Tris (pH 7.4), 300 mM NaCl. 
 
The NRXNβ1 gene construct (His6-NRXNβ140–216 LNS domain lacking the SS4 splice site sequence) 
was cloned into pHYRSF53LA vector. The resulting His-NRXNβ1 construct was expressed from E. 
coli BL21(DE3) in LB medium at 37 °C and induced at an OD600 of 0.8 with 1 mM IPTG, and 
expressed for 4–5 h at 30 °C, after which the cells were collected and suspended in 50 mM Tris HCL 
pH8, 300 mM NaCl. Cells were lysed via sonication. The His6-tagged NRXNβ was purified with 
HisTrapTM column (GE Healthcare) and eluted with 50 mM Tris HCl pH 8, 300 mM NaCl, 250 mM 
imidazole. The protein was further purified with size exclusion chromatography with S-75 Superdex 
10/300 column (GE Healthcare) in 30 mM Tris pH 7.5 and 300 mM NaCl.  
 6 
 
The Fc-His6-pETDuest plasmid was expressed from E. coli BL21(DE3) in LB media at 37 °C and 
induced at an OD600 of 0.6 with 1 mM IPTG, and expressed for 4 hours at 30 °C, after which the 
cells were collected and suspended in 20 mM sodium phosphate pH 8.0, 150 mM NaCl, and 10 mM 
imidazole buffer. Cells were lysed via sonication and supernatant collected, and Fc-His6 protein was 
purified with Ni2+-NTA resin (Qiagen), further purification by size exclusion chromatography was 
done with S-200 Superdex 10/300 column in 1x PBS buffer. 
 
2.2 Assay Development 
We utilized the AlphaScreen technology [28] to develop a binding assay to screen inhibitors for the 
LRRTM2-NRXN interaction. All AlphaScreen assays were performed using AlphaPlate384 
(PerkinElmer) plates. The AlphaScreen reaction consisted of LRRTM2-Fc, His-NRXNβ1, Protein A 
donor and nickel chelate acceptor beads (PerkinElmer) (Fig. 1B) in assay buffer containing 30 mM 
HEPES (pH 7.5), 150 mM NaCl, 1 mg/mL bovine serum albumin (BSA) and 0.2 mM CaCl2. The 
plates were incubated at room temperature and protected from light after addition of the AlphaScreen 
beads. Luminescence was monitored with Tecan infinite M1000 Pro plate reader using the 
AlphaScreen detection module with 100 ms excitation and 300 ms integration times.  
 
Assay sensitivity was first tested in order to establish the optimal concentrations of LRRTM2-Fc and 
His-NRXNβ1, and to obtain a maximal AlphaScreen signal (hook p int). A reaction mixture of 
LRRTM2-Fc and His-NRXNβ1 was prepared in a total volume of 15 µl, followed by incubation at 
room temperature for 2 hours. After the incubation, the AlphaScreen beads were added according to 
the recommended protocol (PerkinElmer): first 5 µl of the acceptor beads were added, followed by 
30 min of incubation and addition of 5 µl of the donor beads, followed by 60 min incubation. The 
final concentrations of LRRTM2-Fc and His-NRXNβ1 were 0-0.5 µM, and 50 µg/ml of the acceptor 
and donor beads. 
 
2.3 Assay optimization 
After assay development, we optimized different assay parameters that included protein incubation 
time, order of addition of beads, bead concentration and bead incubation time. First, we optimized 
the incubation time for the interaction of LRRTM2-Fc and His-NRXNβ1 by testing different times 
from 5 minutes to 2 hours. Second, the order of addition of the beads was determined with three 
sequences, (a) both beads were added together, followed by 90 min of incubation; (b) the acceptor 
beads were added and incubated for 30 min, followed by addition of the donor beads and addition 
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incubation for 60 min, and (c) the donor beads were added and incubated for 30 min, followed by 
addition of the acceptor beads and addition incubation for 60 min. Third, the concentration and 
incubation times of the beads was optimized by testing different concentrations: 20, 10, 5 and 2.5 
µg/ml and incubation times from 60 minutes to 7 hours. Finally, we measured the DMSO tolerance 
of the assay in the  0–10% DMSO concentration range.    
 
Ethylene glycol-bis(2-aminoethylether)-N,N,N’,N’-tetra acetic acid (EGTA) was tested as a positive 
control to inhibit the LRRTM2-NRXN interaction. We measured the effect of 100 µM - 1 mM 
EGTA on the interaction using the selected final assay conditions. For the validation, we also tested 
if EGTA in the range of 50 nM to 5 mM is able to quench the AlphaScreen signal. For this we used 
the commercial AlphaScreen Biotinylated-His peptide assay (PerkinElmer). 
  
2.4 Assay validation  
We validated the assay by measuring the repeatability of the maximal and minimal signals between 
different plates, wells and days. Altogether during 3 days, we measured five plates containing 
maximal and minimal signals; one plate on days 1 and 2, and three plates on day 3. Each plate 
included forty maximal and minimal signal points. Variations of well-to-well, plate-to-plate, and 
day-to-day were calculated as coefficients of variations (CVs). The quality of the data was measured 
with common statistical parameters: signal-to-noise ratio (S/N), signal-to background-ratio (S/B), 
and screening window coefficients (Z’) [30, 31]. 
 
2.5 Library and counter screening  
We screened MicroSource Spectrum compound library with 2000 compounds (obtained from 
FIMM, University of Helsinki) at a single concentration (100 µM). 250 nl of 10 mM compounds 
were transferred to the assay plates with Labcyte Echo 550 acoustic dispenser. 15 µl of the mixture 
of 50 nM LRRTM2-Fc and 50 nM His-NRXNβ1was added to the assay plates. The plates were 
incubated for 5 minutes at room temperature, followed by addition of acceptor and donor bead 
mixture (10 µl, final concentration of 5 µg/ml) according to the optimized procedure, and incubated 
further at room temperature for 3 hours. Each screening plate contained blank wells (AlphaScreen 
beads only), positive controls (inhibition by 0.2 mM EGTA) and negative controls (0% inhibition; no 
EGTA or added compounds). 
 
The counter screening assay was performed in order to rule out false positives obtained from the 
library screening. For this we used Fc-His6 protein, which binds both donor and acceptor beads 
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creating an AlphaScreen signal. Compounds decreasing the signal are considered as false-positives 
due to interaction with the beads or quenching the signal. We performed the counter screening using 
100 µM compound concentration. 15 µl of 16.5 nM Fc-His6 in 25 mM HEPES pH 7.5, 150 mM 
NaCl, 1 mg/ml BSA was added to plate wells followed by addition of 10 µl of AlphaScreen bead 
mixture containing 5 µg/ml of the acceptor and donor beads. The plate was incubated at room 
temperature for 3 hours before reading. 
 
2.6 Potency Measurement  
Concentration response curves for the hit compounds were measured in quadruplicates from 300 µM 
to 1 µM using quarter-logarithmic dilutions. The compounds were transferred to the assay plate 
using Labcyte Echo 550 acoustic dispenser, followed by addition of 15 µl of the mixture of 50 nM 
LRRTM2-Fc and 50 nM His-NRXNβ1. The plates were incubated for 5 minutes at room 
temperature, followed by addition of 10 µl of acceptor and donor bead mixture (final concentration 5 
µg/ml) and an additional incubation at room temperature for 3 hours. The dose-response curves were 
fitted using a four-parameter nonlinear regression analysis (sigmoidal dose-response fitting with 
variable slope) with GraphPad Prism version 5.03 for Windows (GraphPad Software). 
 
2.7 Cell culture and cell-based binding assay  
For cell-based binding assays, we used the mouse LRRTM2 cDNA cloned into pEGFP-N1 plasmid 
vector [20]. We employed the in-cell western blot method to detect the LRRTM2-NRXNα1 
interaction on cell surface with the Odyssey Infrared Imaging System (LI-COR Biosciences) 
following manufacturer’s recommendations. In this assay LRRTM2 was expressed in HEK293T 
cells as a C-terminal GFP-fusion to enable visualization of the protein expression on 96-well cell 
culture plates. The soluble NRXNα1-Fc was added on the cells in a 96-well plate and bi ing was 
detected with anti-human Fc antibody and signal per w ll was read with the Odyssey Imaging 
system.  
 
For the transfection of LRRTM2-pEGFP-N1 into Human embryonic kidney 293T (HEK293T) cells, 
cells were grown to 90% confluency on a T75 flask using DMEM media with 10% FBS 
(ThermoFisher) at 37 °C and 5% CO2. These cells were washed in 1x PBS and trypsinized in 0.05% 
Trypsin-EDTA pH 7.4. Cells were seeded into a poly-L l sine-coated 96 well plate at approximately 
20 000 cells/well, and they were allowed to grow 24 hours at 37° C until they reached confluency of 
90%. After 24 hours, the cells were transfected with LRRTM2-pEGFP-N1 (400 µg/well) plasmid 
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and polyethylenimine (1.2 µg/well). The transfected c lls were incubated at 37° C for 48 hours and 
preceded for in-cell western blot assay.  The LRRTM2-GFP fusion protein expression in transfected 
cells was detected with FloidTM Cell Imaging system (ThermoFischer). For the in-cell western blot 
experiment, LRRTM2-pEGFP-N1 transfected cells were washed with 1xPBS and blocked with EGB 
buffer [22] (168 mM NaCl, 2.6 mM KCl, 10 mM HEPES pH 7.2, 2 mM CaCl2, 2 mM MgCl2, 10 
mM D-glucose, and 5% BSA) for 2 hours at room temperature with slow shaking. Blocking buffer 
was removed and cells were covered in 50 µl of NRXNα1-Fc diluted in EGB buffer with 1% BSA. 
The cells were incubated overnight at 4° C with gentle shaking. Next day, cells were washed with 
1xTBS buffer and were then incubated with 50 µl of 1:200 dilution of secondary antibody (goat anti-
human IgG IRDye 800CW) in EGB buffer with 1% BSA. Following a 60 minute incubation at room 
temperature with gentle shaking, plates were washed with 1xTBS, and further scanned using LI-
COR Odyssey (169 µm resolution and medium quality) with channel (800 nm) intensity of 8. For 
assay development, initially different concentrations of NRXNα1-Fc (10 nM to 1000 nM) were 
used, and the minimum concentration which gave the saturation signal was used for the in-cell 
western blot assay of LRRTM2 and NRXNα1-Fc in presence of inhibitor compounds.  
 
Inhibition assay was performed in triplicates (n=3) and each assay was repeated three times. The 
compounds pyrithione zinc, benzoxiquine, indole-3-carbinol and 6-methoxyharmalan were ordered 
from Sigma-Aldrich, and iodoquinol, pyrvinium pamoate and econazole nitrate were ordered from 
MedChemExpress. For inhibition assay, HEK293T cells transfected with LRRTM2-pEGFP-N1 in 96 
well plate was washed with 1 x PBS and blocked with EGB buffer with 5% BSA for 2 hours at room 
temperature. After blocking for 2 hours, 0.8 µM NRXNα1-Fc diluted in EGB buffer with 1% BSA 
and 300 µM hit compounds were added in each well. Inhibition f the LRRTM2-NRXNα1-Fc 
interaction was detected using 1:200 dilution of goat anti-human IgG IRDye 800CW secondary 
antibody and detected with the LI-COR Odyssey Imaging system. As negative controls for the assay 
we used i) 2 µM purified receptor protein tyrosine phosphatase σ-Fc fusion protein (RPTPσ-Fc) or 
ii) 1-2 µM purified Fc-fragment added on to the cells, and iii) plain HEK293T-cells without 
LRRTM2 expression, but with addition of 1 µM NRXNα1-Fc or iv) HEK293T cell expressing 




3.1 Binding assay for LRRTM2-NRXN β-1 interaction 
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In this paper, we have aimed to establish a screening assay for identification of compounds inhibiting 
trans-synaptic interaction of the postsynaptic LRRTM2 with presynaptic NRXNs. Previously, no 
such assay has been reported for synaptic adhesion proteins. The assay measures the proximity-
generated luminescence using the AlphaScreen technology. An LRRTM2-Fc construct bound to 
Protein A donor beads, and a His-NRXNβ1 construct lacking the SS4 splice site, binding to the 
nickel-chelate acceptor beads were used for the assay. The interaction of LRR domain of LRRTM2 
with the LNS domain of NRXN brings the protein donor beads close to the acceptor beads, and the 
proximity of the beads leads to the transfer of energy due to excitation of donor beads, resulting in 
luminescence emission by acceptor beads at 520-620 nm (AlphaScreen signal, Fig. 1B) [28]. Loss of 
LRRTM2-NRXNβ1 interaction is read as a decrease of in total luminescence in comparison to the 
control. The assay sensitivity was first tested to establish the optimal concentrations of LRRTM2-Fc 
and His-NRXNβ1 to obtain the maximal AlphaScreen signal. This was obtained with 50 nM of 
LRRTM2-Fc and 50 nM of His-NRXNβ1 (Fig. 2A).  
 
Once we had established the assay, we optimized different assay parameters including protein 
incubation time, order of addition of donor and acceptor beads, bead concentration and bead 
incubation time. We first optimized the incubation time for the interaction of LRRTM2-Fc and His-
NRXNβ1. No major difference in the AlphaScreen signal was detected with increase in incubation 
time, therefore we selected the shortest 5 min protein incubation time (Fig. 2B). To increase 
robustness of the assay, we tested different order of addition of beads (Fig. 2C). Acceptable signal 
window for screening was obtained after mixing the donor and acceptor beads followed by addition 
of bead mixture in the reaction mixture containing LRRTM2-Fc and His-NRXNβ1, and further 
incubation for 90 minutes. In order to decrease the running cost of the assay, we tested different 
beads concentrations and incubation times, and acceptabl  signal was detected with 5 µg/mL of the 
acceptor and donor bead mixture, followed by incubation time of 3 hours (Fig. 2D and 2E). The aim 
was to achieve robust screening assay with high signal-to-noise ratio, with reduced the running costs. 
We found the following protocol to be most optimal for the assay in terms of the both robustness and 
cost-effectiveness: 15 µl of a reaction solution cotaining 50 nM LRRTM2-Fc and 50 nM of His-
NRXNβ1was incubated for 5 minutes, before adding 10 µl of 5 µg/mL the AlphaScreen acceptor and 
donor bead mixture followed by incubation of 3 hours before signal detection. This would result in 
approximately 0.15$ costs per well for larger assay (e.g. with tens of thousands of conditions) 
excluding compound and dispensing costs. 
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The LRRTM2-NRXN interaction has clearly been shown to be calcium dependent in cell-based 
assays [3, 17]. Therefore, we tested if we could use the calcium chelator EGTA as a control for 
inhibition the interaction. Experiments showed that addition of 0.5 mM EGTA decreased the 
AlphaScreen signal down to ca. 5% indicating loss of the LRRTM2-NRXN interaction at 0.2 mM 
Ca2+-ion concentration, while initial 2 mM CaCl2
.used in the assay was too high to be inhibited (Fig. 
2F). It was further verified with Biotinyled-His petide (Biotinylated-HIS, PerkinElmer) that  EGTA 
did not interfere with the assay itself and EGTA indeed did not quench the AlphaScreen signal at the 
concentrations used through e.g. Ni-chelation (Fig. 2G).  
 
We also measured the affinity for the LRRTM2-NRXNβ1 interaction with purified soluble proteins 
by surface plasmon resonance (SPR) in presence of Ca2+, and found it to be similar to that reported 
recently by others [20], with a Kd-value of 6.6 µM. We further confirmed by SPR that in presence of 
2 mM EGTA in the buffer the affinity was lost, as only 2.4% of signal was left at 50 µM NRXNβ1 
concentration (Supplementary material, Suppl. Fig. 1).  
 
Next, since DMSO is a commonly used solvent for the compound libraries, we tested the DMSO 
tolerance of the assay. The assay was found to tolera e DMSO up to the tested 10% concentration. 
No substantial deviation in signal between control reaction without DMSO and the 10% DMSO 
containing reaction was found (Fig. 2H). 
 
In order to validate the quality of the assay for screening, we tested the changes in the plate-to-plae 
and day-to-day minimal and maximal signals with five different plates. The average Z’ value for all 
the plates was 0.82 with high signal-to-noise ratio, indicating that the screening assay was robust 
(Table 1). 
 
Table 1. Assay performance. 
S/B 14.9 ± 0.9 
S/N 19.0 ± 4.9 
Z’  0.82 ± 0.04 
Well to well CV (max/min,%) 5.04  ± 0.98 / 8.35 ±  5.8 
Plate to plate CV (%) * 4.7 
Day-to-day CV (%)* 4.17 (2.83-6.59) 





3.2 Screening and potency measurements 
We next performed a validatory screening assay using the MicroSource Spectrum library of 2000 
compounds, which includes drugs, natural products, and bioactive compounds. The compounds were 
used at 100 µM concentration. The assay performed well in screening, with an average Z’ of 0.8 ± 
0.02 over six plates calculated from the control wels. We obtained 92 initial hits with a 4.6% hit-
rate, all of which decreased the AlphaScreen signal at least to same extent as EGTA, indicating 
potential inhibition of LRRTM2-NRXNβ1 interaction (Fig. 3A).   
 
However, as the hit-rate was high due to the high concentration used, and likely due to the nature of 
the validatory compound library, we also controlled for false positives through counter screening.  
Possible mechanisms of non-specific interference with the AlphaScreen signal that the compounds 
could manifest include 1) by acting as singlet oxygen quenchers, 2) by interfering with the 
production of luminescence signal itself, or 3) binding to the donor or acceptor beads and interfering 
with the ligand tag (His-tag or Fc-fragment) binding. In order to rule out false positives we 
performed a counter screen with the initial 92 hits and His-tagged Fc-fragment binding both the 
donor and acceptor beads in absence of the actual target interactor proteins to monitor for the 
AlphaScreen signal. From this we obtained 12 hits tat did not interfere with the output signal, out of 
the initial 92 hits (Fig. 3B), 80 compounds thus interfered with the assay and were excluded. These 
were not analyzed further, but the 12 hit compounds that did not interfere in the counter screen were 
taken further for validation. The final hit-rate based on the set hit limit after counter screening was 
thus 0.6%. 
 
Dose-response curves were measured for further validation for the 12 hit compounds (Fig. 4), which 
revealed four of the initial hits (solasodine, meta-cresyl acetate and harmaline and penicillin) as 
actual false positives. The IC50 values for the remaining eight hit compounds were between 30-76 
µM (Fig. 4 & 5).  These were further checked for pan-assay interference compounds (PAINS) 
patterns to recognize possible frequent false hits, and  from these early hit compounds only 
iodoquinol and pyrvium pamoate (Fig. 5) contained rcognizable PAINS and aggregation patterns 
when analysed with the ZINC server (http://zinc15.docking.org/patterns/home/) [33]. Hence, the 
results on these two compounds should be further validated, in case these compounds are used and 
developed further.   
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3.3 Cell binding assay 
Next, we performed an in-cell western blot assay to detect the binding affinity of NRXNα1-Fc to 
LRRTM2 expressed on HEK293T cells in order to use this as an orthogonal assay for the 
verification of inhibition of binding, as explained in the methods. We measured the apparent binding 
affinity of soluble dimeric NRXNα1-Fc to LRRTM2 on the cell surface to be 154 ± 18 nM (Fig. 
6A). The negative controls showed no detectable signal (Fig. 6C), which confirmed the assay is 
specific for detecting the interaction between LRRTM2 and NRXNα1.  
 
For the orthogonal in-cell western assay for inhibitor hit validation, we used 0.8 µM NRXNα1-Fc as 
ligand for LRRTM2 interaction. We measured the inhibition of LRRTM2 and NRXNα1-Fc 
interaction with 300 µM AlphaScreen hit compounds, that were separately ordered for this assay. 
The assay shows average inhibition rate of 82% for ec nazole nitrate, 60% for pyrithione zinc,  54% 
for 6-methoxyharmalan, 54% for iodoquinol, 47% for benzoxiquine, and 46% for pyrvinium 
pamoate, while indole-3-carbinol did now show any ihibition. As a control, we tested for inhibition 
by harmaline for which the IC50-value could not be determined, and it showed only 3.3 % inhibition 
of the signal also in the cell-binding assay (Fig. 6B). Cetylpyridinium chloride was excluded from 




The presynaptic NRXNs are in particular attractive targets as they have multiple post-synaptic 
ligands [3], and several if not all of these proteins have been linked genetically to neuronal disorders, 
most probably as their misexpression will lead to synapse loss and imbalance of inhibitory/excitatory 
synapse-ratio and regulation of signaling in the brain. Direct studies of the effects of these proteins in 
neuronal culture or tissue in animal models remain quite challenging, and hence small molecule 
chemical probes would be highly valuable in understanding the functions of various adhesion 
complexes at the cellular or tissue level and in anm l models.   
 
In the current paper we establish a high-throughput me hod to assay for inhibitors of the synaptic 
NRXN-LRRTM interaction. The developed AlphaScreen-assay detecting protein-protein interaction 
is suitable for finding initial hits inhibiting neuronal synaptic adhesion protein interactions. Assay 
performs well based on statistical parameters (Table 1) highlighting the robustness and applicability 
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for screening of large compound libraries in singlets. The assay tolerates DMSO (up to at least 10%), 
enabling high compound concentrations to be screened. H re we used high compound concentrations 
in the validatory screening, in order to demonstrate both the performance and possibility for 
identifying hit compounds. High concentration of compounds challenges most screening assays 
through quenching the signal and affecting assay regents. AlphaScreen assay suffers also from 
interference resulting in a large number of false positives in the assay setup and that makes counter-
screening strategy necessary [34] . We used an Fc-His6 construct for counter screening, and indeed 
found out that majority of the compounds inhibiting the signal where not inhibiting protein-protein 
interaction, but affected the signal by another mechanism.  
 
In addition to counter screening it is important to measure the discovered hit effectively with an 
orthogonal assay. With the described cell-based assay we demonstrated that AlphaScreen assay can 
indeed be used to discover function compounds interfering with the LRRTM2-NRXN interaction. 
The assay can be readily automated for high-throughp t screening and it can be also miniaturized for 
the high density microplates. The obtained current hit compounds have relatively low affinities based 
on their IC50-values and are limited in their usefulness as chemical probes. Based on the orthogonal 
assay however, several compounds have specific inhibitory potential also in cellular environment 
and varied in the efficacy: while indole-3-carbinol had no effect, econazole nitrate was clearly the 
most promising scaffold from this compound selection in a cell-based assay (Fig. 6). Furthermore, 
some of the compounds active in the cell-based assay are rather small (e.g. benzoxiquine and 6-
methoxyharmalan, Fig. 5) and could possibly be optimized for increased potency. An interesting 
finding is the very different effects of harmaline and 6-methoxyharmalan, which are isomers of each 
other, yet, harmaline (7-methoxyharmalan) was not active in the validatory assays.  
 
The current study provides proof-of-principle for the assay and shows that it can be utilized for 
screening, although larger compound sets are needed to find specific high affinity binder scaffolds 
for further development. Together with the cell binding assay we provide a set of tools for the 
discovery of protein-protein interaction inhibitors. The assay was developed for LRRTM2-NRXN 
interaction, but could be generalizable for other adhesion proteins. This is in particular true for other 
NRXN-ligand interactions, e.g. neuroligins and LRRTMs recognize the same binding epitope on 
NRXNs [14, 35, 36]. Overall, to our knowledge this is the first published account on development of 
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Figure 1. Protein organization, interactions and the assay principle. A) Domain organization of 
LRRTM2 and NRXN. Main features of LRRTM2 and NRXN are indicates as: L(1-6), LNS domains 
1-6; E(1-3), EGF domains 1-3; and P; PDZ binding motif. LRRTM2: white ellipsoids mark the LRR 
repeats 1-10, and grey ellipsoids the LRRNT and LRRCT regions. LRRTMs bind to the LNS6 
domain of NRXN-α/NRXN-β. B) Schematic representation for the interaction of LRRTM2 with 
NRXN using the AlphaScreen assay. The interaction of LRR domain of LRRTM2 (red) with the 
LNS domain of NRXN (blue) brings the protein A donor beads closer to nickel chelate acceptor 
beads. The excitation of protein A donor beads at 680 nm convert the ambient oxygen to a excited 
singlet state. If an acceptor bead is within the proximity, energy is transferred from the singlet 
oxygen to the Acceptor bead, subsequently culminating in light production at 520-620 nm 
(AlphaScreen signal).  
 
Figure 2. AlphaScreen assay development and optimization. A) The sensitivity of the 
AlphaScreen assay was tested with concentration series of LRRTM2-Fc and His-NRXNβ-1. The 
maximal signal (hook point) was determined for the assay, measured in counts per second (cps).  The 
reaction mixture containing LRRTM2-Fc and His-NRXNβ-1were incubated for 2 hours, followed by 
the addition of acceptor beads and incubation for 30 minutes, after which donor beads was added 
with additional incubation for 60 minutes. B) The protein incubation time of LRRTM2-Fc and His-
NRXN β-1 was tested for different time periods using develop d AlphaScreen assay. C) The order of 
addition of the AlphaScreen beads was tested: (a) both eads were added together, followed by 90 
min of incubation; (b) the acceptor beads were added and incubated for 30 min, followed by addition 
of the donor beads and addition incubation for 60 min, and (c) the donor beads were added and 
incubated for 30 min, followed by addition of the acceptor beads and addition incubation for 60 min. 
D) The optimal bead concentration was determined by incubating reaction mixture containing 
LRRTM2-Fc and His-NRXN β-1for 5 minutes and addition of various beads concentration and 
additional incubation for 90 minutes. E) The effect of bead incubation time to the signal level was 
optimized using a 5 µg/mL each bead concentration. F ) The effect of addition  of 50 nM to 5mM 
EGTA on the beads using the standard AlphaScreen kit (Biotinylated-HIS, PerkinElmer) G) 
Inhibition of NRXN-LRRTM2 interaction by EGTA at either at 2 mM (squares) or 0.2 mM Ca2+ 
(dots) concentration. In the experiment 50 nM each of LRRTM2-Fc, His-NRXNβ-1and 100 µM to 1 
mM EGTA were mixed and incubated for 5 minutes before the addition of donor/acceptor beads. 
The results are presented as %-signal compared to the EGTA-free control. H) DMSO tolerance 
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assayed with reaction mixture containing 50 nM each of LRRTM2-Fc and His-NRXN β-1 and 0-
10% DMSO, incubated for 5 minutes before the addition of donor and acceptor beads. The results 
are presented as signal percentage compare to the 0% DMSO control.  
 
Figure 3. Primary screen results and counter screen results for identification of false positives. 
A) LRRTM2-Fc and His-NRXNβ-1 interaction screened against the MicroSource Spectrum 
compound library (%-inhibition plotted against compounds). Relative inhibition of the compounds 
calculated from the positive controls (0% inhibition) on the plate. The hit limit was set to >88% 
inhibition, based on the EGTA control (88% inhibition). B) A counter-screen experiment with the 
positive hit compounds from the initial screen with a Fc-His6 protein to rule out non-specific 
inhibition due to interference with interaction with he beads.  Compounds that showed less than 
30% inhibition (dashed line) were taken forward. 
 
Figure 4. Dose–response measurements to determine IC50-values of the hit compounds. A) 
iodoquinol B) cetylpyridinium chloride C) benzoquinone D) pyrithione zinc E) indole-3-carbinol F) 
pyrvinium pamoate G) econazole nitrate H) 6-methoxyarmalan. Dose–response measurements were 
done with hit compounds obtained after counter screen experiment. The compounds were assayed in 
quadruplicates using quarter -logarithmic dilutions. Determined IC50-values are given as inserts in A 
to H for each compound.  
 
Figure 5. Structures of the hit compounds. Compounds are labeled A-H as in Figure 4. A) 
iodoquinol B) pyrithione zinc C) benzoquinone D) pyrvinium pamoate E) indole-3-carbinol  F) 
econazole nitrate G) 6-methoxyharmalan. Molecular weight of each compounds in Daltons (Da) is 
included in brackets.  
 
Figure 6. Cell-based binding assay and validation of the hit compounds with orthogonal in-cell 
western blot assay. A) Cell binding assay of soluble NRXNα-1-Fc (0-1000nM) to LRRTM2 on the 
HEK293T cells. Detected in-cell western blot signals (right) and equilibrium binding curve (left). B) 
Validation of the hit compounds from primary screen with the in-cell western blot assay. Detected 
in-cell western blot signals (right) and intensities detected in the presence of 300 µM compounds 
(left). Relative intensity of the assays was calculated from the positive control (100% intensity). C) 
Controls for the cell binding assay. From left; plain (HEK293T) cells (“-/-“) , HEK293T cells with 
LRRTM2 transfected (“LRRTM2/ -“), plain HEK293T cells with ligand NRXNα-1-Fc added (“ - / 
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NRXN”) , HEK293T (LRRTM2 expressed) with ligand RPTs-Fc added (“LRRTM2/RPTPσ”), and 

























































































































































Pyrithione zinc  (317.70 Da)
Indole-3-carbinol (147.17 Da)
Econazole nitrate (444.69 Da)
6-methoxyharmalan (214.26 Da)



















• AlphaScreen assay for inhibitors of synaptic adhesion protein function is described 
 
• Optimized assay was robust for screening of NRXN-LRRTM interaction inhibitors 
 
•  Eight early hit compounds were discovered 
 
• Orthogonal cell assay is described which can be used to confirm the potency of hits 
 
 
